Cargando…

Costunolide covalently targets NACHT domain of NLRP3 to inhibit inflammasome activation and alleviate NLRP3-driven inflammatory diseases

The NLRP3 inflammasome’s core and most specific protein, NLRP3, has a variety of functions in inflammation-driven diseases. Costunolide (COS) is the major active ingredient of the traditional Chinese medicinal herb Saussurea lappa and has anti-inflammatory activity, but the principal mechanism and m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Haowen, Chen, Jiahao, Chen, Pan, Li, Weifeng, Shao, Jingjing, Hong, Shanshan, Wang, Yi, Chen, Lingfeng, Luo, Wu, Liang, Guang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978959/ https://www.ncbi.nlm.nih.gov/pubmed/36873170 http://dx.doi.org/10.1016/j.apsb.2022.09.014

Ejemplares similares

MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition
por: Vande Walle, Lieselotte, et al.
Publicado: (2019)

Extent of Ischemic Brain Injury After Thrombotic Stroke Is Independent of the NLRP3 (NACHT, LRR and PYD Domains-Containing Protein 3) Inflammasome
por: Lemarchand, Eloise, et al.
Publicado: (2019)

Correction: MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition
por: Walle, Lieselotte Vande, et al.
Publicado: (2019)

BAFF-driven NLRP3 inflammasome activation in B cells
por: Lim, Ken-Hong, et al.
Publicado: (2020)

NLRP3 Inflammasome Pharmacological Inhibitors in Glycyrrhiza for NLRP3-Driven Diseases Treatment: Extinguishing the Fire of Inflammation
por: Wang, Zhilei, et al.
Publicado: (2022)

Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity
por: He, Hongbin, et al.
Publicado: (2018)

FMDV Leader Protein Interacts with the NACHT and LRR Domains of NLRP3 to Promote IL-1β Production
por: Choudhury, Sk Mohiuddin, et al.
Publicado: (2021)

Deciphering the ATP-binding mechanism(s) in NLRP-NACHT 3D models using structural bioinformatics approaches
por: Maharana, Jitendra, et al.
Publicado: (2018)

Taurine Alleviates Sympathetic Innervation by Inhibiting NLRP3 Inflammasome in Postinfarcted Rats
por: Lee, Cheng-Che, et al.
Publicado: (2021)

Covalent targeting as a common mechanism for inhibiting NLRP3 inflammasome assembly
por: Stanton, Caroline, et al.
Publicado: (2023)

Tranilast directly targets NLRP3 to treat inflammasome‐driven diseases
por: Huang, Yi, et al.
Publicado: (2018)

Inhibiting the NLRP3 Inflammasome
por: El-Sharkawy, Lina Y., et al.
Publicado: (2020)

NF-κB-Gasdermin D (GSDMD) Axis Couples Oxidative Stress and NACHT, LRR and PYD Domains-Containing Protein 3 (NLRP3) Inflammasome-Mediated Cardiomyocyte Pyroptosis Following Myocardial Infarction
por: Lei, Qian, et al.
Publicado: (2018)

Electroacupuncture Alleviates Osteoarthritis by Suppressing NLRP3 Inflammasome Activation in Guinea Pigs
por: Wang, Zhankui, et al.
Publicado: (2020)

The NLRP3 and NLRP1 inflammasomes are activated in Alzheimer’s disease
por: Saresella, Marina, et al.
Publicado: (2016)

Role of NLRP3 inflammasome in diabetes and COVID-19 role of NLRP3 inflammasome in the pathogenesis and treatment of COVID-19 and diabetes NLRP3 inflammasome in diabetes and COVID-19 intervention
por: Zhang, Jiayu, et al.
Publicado: (2023)

Research Progress of Mitochondrial Mechanism in NLRP3 Inflammasome Activation and Exercise Regulation of NLRP3 Inflammasome
por: Zhang, Tan, et al.
Publicado: (2021)

Rutin alleviates ventilator-induced lung injury by inhibiting NLRP3 inflammasome activation
por: Chen, Shengsong, et al.
Publicado: (2023)

Exosomes Regulate NLRP3 Inflammasome in Diseases
por: Li, Zhangwang, et al.
Publicado: (2022)

The role of NLRP3 inflammasome in hepatocellular carcinoma
por: Zhao, Huijie, et al.
Publicado: (2023)

The leucine-rich repeat (LRR) domain of NLRP3 is required for NLRP3 inflammasome activation in macrophages
por: Duan, Yanhui, et al.
Publicado: (2022)

The NLRP3 inflammasome: role in the pathobiology of chronic pain
por: Chen, Chen, et al.
Publicado: (2023)

NLRP3 licenses NLRP11 for inflammasome activation in human macrophages
por: Gangopadhyay, Anu, et al.
Publicado: (2022)

The role of the NLRP3 inflammasome in gout
por: Kingsbury, Sarah R, et al.
Publicado: (2011)

The Role of the NLRP3 Inflammasome in Fibrosis
por: Artlett, Carol M
Publicado: (2012)

NLRP3 Inflammasome and MS/EAE
por: Inoue, Makoto, et al.
Publicado: (2013)

NLRP3 Inflammasome and Pathobiology in AMD
por: Celkova, Lucia, et al.
Publicado: (2015)

Role of the NLRP3 inflammasome in cancer
por: Moossavi, Maryam, et al.
Publicado: (2018)

Spotlight on the NLRP3 inflammasome pathway
por: Groslambert, Marine, et al.
Publicado: (2018)

Regulation of NLRP3 Inflammasome by Phosphorylation
por: Song, Nan, et al.
Publicado: (2018)

Role of NLRP3 Inflammasomes in Atherosclerosis
por: Karasawa, Tadayoshi, et al.
Publicado: (2017)

NLRP3 inflammasome in endothelial dysfunction
por: Bai, Baochen, et al.
Publicado: (2020)

Pharmacological Inhibitors of the NLRP3 Inflammasome
por: Zahid, Ayesha, et al.
Publicado: (2019)

NLRP3 Inflammasome and Inflammatory Diseases
por: Wang, Zheng, et al.
Publicado: (2020)

Role of the NLRP3 Inflammasome in Preeclampsia
por: Shirasuna, Koumei, et al.
Publicado: (2020)

Neurodegenerative Disease and the NLRP3 Inflammasome
por: Holbrook, Jonathan A., et al.
Publicado: (2021)

Targeting the NLRP3 Inflammasome in Glaucoma
por: Coyle, Sophie, et al.
Publicado: (2021)

The NLRP3-Inflammasome in Health and Disease
por: Perri, Anna
Publicado: (2022)

The role of mitochondria-associated membranes mediated ROS on NLRP3 inflammasome in cardiovascular diseases
por: Zhao, Jiahao, et al.
Publicado: (2022)

Calycosin Alleviates Doxorubicin-Induced Cardiotoxicity and Pyroptosis by Inhibiting NLRP3 Inflammasome Activation
por: Zhang, Lei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_38h46osj75pgnslsb0j19c12pl